English Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil

Archivos de Medicina

  • ISSN: 1989-5216
  • Índice h de la revista: 22
  • Puntuación de cita de revista: 4.96
  • Factor de impacto de la revista: 4.44
Indexado en
  • Genamics JournalSeek
  • Infraestructura Nacional de Conocimiento de China (CNKI)
  • Directorio de indexación de revistas de investigación (DRJI)
  • OCLC-WorldCat
  • Convocatoria de búsqueda
  • Publón
  • Fundación de Ginebra para la Educación e Investigación Médica
  • pub europeo
  • Google Académico
  • Laboratorios secretos de motores de búsqueda
Ver más
Comparte esta página

Abstracto

Third-line Antiretroviral Therapy in a Nigerian Clinic: Case Series

Herbertson EC, Gbajabiamila TA, Ekama SO, Idigbe IE

There is limited experience with use of third line regimen in sub-Saharan Africa. It is expected that about 10% of those on 1st line treatment will fail and to be switched to 2nd line. Another 10% of those on 2nd line are also expected to fail and be switched to 3rd line. Recommendation for 3rd line in the guidelines is to include new drugs with minimal risk of cross resistance to previously used regimens such as Integrase Inhibitors and second-generation NNRTIs and PIs. We present three cases on third-line regimen on boosted Darunavir, Etravirine and Raltegravir. 66.7% viral suppression was achieved after four years of access to the medication. The third line regimen was well tolerated by the three cases and there was no report of serious adverse drug reaction. Adherence was also good in all cases. Third line regimen is effective but there is need to secure access. The cases reported had to interrupt treatment because access to free third-line ART was terminated by implementing partners. The Nigerian government is encouraged to take up the responsibility to provide third line regimen.